BioCopy accelerates the fight against cancer

Shorten research and development time for cancer drugs from 3 years to 12 months and significantly reduce development costs

24-Mar-2025 - The German-Swiss biotechnology start-up BioCopy has secured new capital of 8 million euros. This sum is an important step for the company on its mission to produce more effective cancer drugs in the shortest possible time and at significantly lower costs. The company is supported by a group of ...

Tool identifies specific viruses to combat dangerous bacteria

Research team shortens the search for attackers that can wipe out multiresistant pathogens – with the aim of treating infections without antibiotics

18-Mar-2025 - A newly developed laboratory tool can, within hours, help to identify specific viruses which can be used to destroy variants of the dangerous pathogenic bacteria Staphylococcus aureus. Viruses of bacteria, known as bacteriophages, offer an alternative approach to antibiotics in treating ...

Nature relieves physical pain: pain-related signals in the brain are reduced

This effect even occurs with virtual nature – such as nature videos

17-Mar-2025 - In a new study, an international team of neuroscientists led by the University of Vienna has shown that experiencing nature can alleviate acute physical pain. Surprisingly, simply watching nature videos was enough to relieve pain. Using functional magnetic resonance imaging, the researchers found ...

Medical infusion bags can release microplastics

Researchers estimate that each bag of infusion fluid could deliver about 7,500 microplastics directly into the bloodstream

14-Mar-2025 - Microplastics have been found almost everywhere that scientists have looked for them. Now, according to research published in the ACS partner journal Environment & Health, these bits of plastic — from 1 to 62 micrometers long — are present in the filtered solutions used for medical intravenous ...

Sun Pharma to Acquire Checkpoint Therapeutics

11-Mar-2025 - Sun Pharmaceutical Industries Limited and Checkpoint Therapeutics, Inc. announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company. Checkpoint is a Nasdaq-listed commercial-stage company focused on developing ...

Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept

10-Mar-2025 - Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch with the closing of a $187.0 million Series A financing round. This financing was led by Frazier Life Sciences with ...

New approaches in cancer research

Tumour-on-chip model supports preclinical drug development on pancreatic cancer

10-Mar-2025 - The biotech company Dynamic42, a specialist in organ-on-chip technology, has made a significant advance in pancreatic cancer drug research in collaboration with the research team of Prof. Dr. Nicole Teusch at the Institute of Pharmaceutical Biology and Biotechnology at Heinrich Heine University ...

Immune cells with a dual role: switching between protection and attack

Rsearchers show that a certain type of immune cell acts more flexibly than previously thought - with potential for new therapeutic approaches

03-Mar-2025 - As part of the innate immune system, dendritic cells are part of the body's first line of defense against infections. They recognize pathogens and coordinate the immune response. An international team led by Professor Barbara Schraml from LMU's Biomedical Center has now comprehensively ...

Personalized cancer therapy with a "mini-tumour" and digital twin

03-Mar-2025 - Improving treatment recommendations for colorectal cancer patients: This is the aim of a collaborative project between the University of Bonn, the company ESQlabs and the University Hospital Bonn (UKB), funded by the Federal Ministry of Education and Research. "ISPOT-K" combines organoids derived ...

Fuse Vectors secures $5.2m to advance cell-free gene therapy technology, led by HCVC

Danish biotech replaces cell-based methods with revolutionary cell-free technology, making gene therapy more accessible

28-Feb-2025 - Gene therapy's biggest obstacle isn't science - it's manufacturing. While the field races forward with breakthrough treatments, production remains stuck in the 1980s, relying on unpredictable cell-based methods that make therapies costly and slow to develop. Today, Fuse Vectors announces $5.2 ...